Artivion
Open
$35.74
Prev. Close
$35.74
High
$35.74
Low
$35.71
Market Snapshot
$1.64B
168.0
-0.31
$388.54M
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
emptyResult
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
Recently from Cashu

Artivion Gains FDA Approval for NEXUS Aortic Arch System, Eyes Acquisition of Endospan
In a significant advancement within the cardiovascular device sector, Artivion, Inc. receives FDA approval for the Premarket Approval (PMA) of the NEXUS Aortic Arch System, developed by Endospan. This…

Artivion's NEXUS Approval Boosts Growth Potential in Aortic Disease Treatment Market
Artivion makes significant strides in aortic disease treatment with the FDA's recent approval of its NEXUS Aortic Arch System. This innovative technology is pivotal for patients suffering from aortic…
Artivion Receives FDA Approval for NEXUS® Aortic Arch System, Enhancing Aortic Disease Treatments
Artivion, Inc. (NYSE: AORT) secures FDA approval for its NEXUS® Aortic Arch System, revolutionizing treatment for aortic arch disease. This approval marks a major advancement in minimally invasive car…
Surge in Insider Sales Raises Concerns About Artivion's Future Direction and Executive Confidence
Artivion Insider Sales Surge Raises Questions About Future Direction Artivion, a prominent player in the medical technology sector that specializes in cardiovascular solutions, has recently seen a wav…